|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM361763263 |
| 003 |
DE-627 |
| 005 |
20231226085827.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109754
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1205.xml
|
| 035 |
|
|
|a (DE-627)NLM361763263
|
| 035 |
|
|
|a (NLM)37678720
|
| 035 |
|
|
|a (PII)S1521-6616(23)00517-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Santos, Gabrielle de Mello
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Should we be targeting type 1 interferons in antiphospholipid syndrome?
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.10.2023
|
| 500 |
|
|
|a Date Revised 06.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a Systemic autoimmune diseases are characterized by increased production of type I interferon (IFN-1) and upregulation of IFN-1-inducible genes, suggesting an important role of the IFN-1 pathway in their pathogenesis. Recent studies have demonstrated increased IFN-1 expression in both primary and secondary antiphospholipid syndrome (APS), along with increased toll-like receptor type 9 activity and plasmacytoid dendritic cell function. The increasing knowledge of the association between IFN-1 and APS pathology may provide a rationale for conducting clinical trials to assess the efficacy of IFN-1-targeting drugs in reducing APS-related complications. In this narrative review, we summarize the current knowledge on the role of IFN-1 in APS pathogenesis, explore its clinical implications, and examine the existing evidence regarding therapeutic options that have been investigated to date
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Antiphospholipid syndrome
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a IFN-1 antagonists
|
| 650 |
|
4 |
|a Plasmacytoid dendritic cells
|
| 650 |
|
4 |
|a Type-1 interferons
|
| 650 |
|
7 |
|a Interferon Type I
|2 NLM
|
| 650 |
|
7 |
|a Interferons
|2 NLM
|
| 650 |
|
7 |
|a 9008-11-1
|2 NLM
|
| 700 |
1 |
|
|a Saldanha, Artur
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Orsi, Fernanda Andrade
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 255(2023) vom: 15. Okt., Seite 109754
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:255
|g year:2023
|g day:15
|g month:10
|g pages:109754
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109754
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 255
|j 2023
|b 15
|c 10
|h 109754
|